Clinical trial · Interventional
68Ga-DOTATATE PET for Management of Neuroendocrine Tumors
The Clinical Impact of 68Ga-DOTATATE PET in the Management of Patients With Neuroendocrine Tumors
NCT03873870CI-TRIAL-00073037completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a research study to collect information regarding usefulness of positron emission tomography (PET) scans using a special dye called 68Ga-DOTATATE for patients with neuroendocrine tumours by determining the number of of patients whose clinical management was changed as a result of the scans.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroendocrine Tumors | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 68Ga -DOTATATE PET scans | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 68Ga -DOTATATE PET scan
- description
- Single arm study.
- interventionNames
- Diagnostic Test: 68Ga -DOTATATE PET scans
Primary outcomes (1)
- measure
- Detection of additional disease and/or change in extent of disease after 68Ga-DOTATATE PET
- timeFrame
- NA. One time visit for 68Ga-DOTATATE PET scan
- description
- Detection of additional disease and/or change in extent of disease after 68Ga-DOTATATE PET
Secondary outcomes (1)
- measure
- To determine the proportion of patients with NET (or clinical suspicion of NET) in whom intended clinical management prior to PET is changed after 68Ga-DOTATATE PET.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 14 Years
Show eligibility criteria text
Inclusion Criteria: * Able to undergo PET/CT without sedation * Any of the following indications: * Group A. Identification of primary tumor: For the initial diagnosis of patients with clinical (e.g., signs, symptoms) and/or biochemical (e.g., tumor markers) suspicion of neuroendocrine tumours (NETs) but for whom conventional imaging is negative or equivocal or for whom biopsy is not easily obtained. * Group B. Staging: For the staging of patients with localized primary NETs and/or limited metastasis where definitive surgery is planned. * Group C. Restaging: Restaging of patients with NET where surgery or peptide-receptor radiotherapy (PRRT) is being considered; OR, where conventional imaging is negative or equivocal at time of clinical and/or biochemical progression. * Group D. As a problem-solving tool: As a problem-solving tool in patient with NET when confirmation of site of disease and/or disease extent may impact clinical management. * Approved by a review panel if Group D. Exclusion Criteria: * Inability to provide informed consent. * Contraindication for PET examination as per institutional safety guidelines, including but not limited to pregnancy, or inability to lie still for PET examination. * Need for full sedation to undergo PET/CT scan.
References
Publications (0)
Data not yet available
No reference posted for this study.